logo
Plus   Neg
Share
Email

Medtronic Plc Q4 Profit Beats Estimates - Quick Facts

Medtronic plc (MDT) said its fourth-quarter non-GAAP net income and non-GAAP diluted EPS were up 7 percent and 8 percent, respectively, from previous year. Adjusting for negative impact from foreign currency, fourth-quarter non-GAAP diluted EPS increased 9 percent. Revenue grew 3.6% organic, for the quarter. Looking forward, for fiscal 2020, Medtronic projects revenue growth to approximate 4.0 percent on an organic basis.

For the fourth-quarter, non-GAAP earnings per share was $1.54 compared to $1.42 previous year. On average, 25 analysts polled by Thomson Reuters expected the company to report profit per share of $1.47 for the quarter. Analysts' estimates typically exclude special items.

Fourth-quarter revenue was $8.1 billion, flat as reported. Analysts expected revenue of $8.11 billion, for the quarter.

For fiscal 2020, the company expects non-GAAP EPS in the range of $5.44 to $5.50, including an estimated 10 cent negative impact from foreign exchange based on current rates. Analysts expect the company to report profit per share of $5.44.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Zoom Video Communications (ZM) gained 4% on extended session Tuesday after the video conferencing software company reported a first-quarter results that trumped Wall Street estimates and issued a outlook for the second and full year 2021 that is expected to beat current expectations. First-quarter... The National Retail Federation Chief Economist Jack Kleinhenz said it was too early to say how quickly or smoothly the U.S. economy would stage a recovery following the "sizable disruptions" due to the coronavirus pandemic. However, he noted that the reopening of businesses and the resumption of economic activity is a significant step forward. Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products.
Follow RTT